Abstract:Background: Itch is the most bothersome symptom reported by patients with psoriasis. Safe and effective treatments for psoriasis that also address itch are needed. Objectives: To report effects of roflumilast cream on itch-related outcomes from a Phase 2b trial. Methods: Adults with chronic plaque psoriasis were randomized to roflumilast 0.3%, roflumilast 0.15%, or vehicle once-daily for 12 weeks. Psoriasis severity was assessed via the Investigator Global Assessment (IGA; a 5-point scale assessing plaque thickening, scaling, and erythema ranging from 0 [clear] to 4 [severe]) and ≥ 2 on a modified Psoriasis Area and Severity Index (PASI-HD, which combines severity of lesions and area affected, ranging from 0 [no disease] to 72 [maximal disease], with the actual percentage of the anatomical area involved in those patients with < 10% of anatomical area involved [e.g., 0.1 for 1% to 0.9 for 9%]). Itch was evaluated via Worst Itch Numeric Rating Scale (WI-NRS), Psoriasis Symptom Diary (PSD) Items 1 (severity of itch) and 2 (bother of itch), and itch-related sleep loss NRS scores. Post hoc correlation analyses between WI-NRS and PASI, WI-NRS and itch-related sleep loss, and WI-NRS and DLQI were also performed. Results: Roflumilast-treated patients had significantly greater improvements than vehicle-treated patients in WI-NRS and PSD Items 1 and 2 beginning at Week 2 and in itch-related sleep loss Weeks 6 through 12. Among patients with baseline WI-NRS ≥ 6, significantly more patients achieved ≥ 4-point improvement with roflumilast than with vehicle as early as Week 2. Itch severity had low correlation with PASI while WI-NRS and IGA were not always aligned. Limitations: The first assessment was at 2 weeks, limiting the ability to assess early onset of itch response. Conclusion: Roflumilast cream improved itch and itch-related sleep loss associated with chronic plaque psoriasis. Gov identifier: NCT03638258.

[Two cases of primary female urethral cancer].

Proteins: Links in the Tissue

[Effect of paromomycin on enterobacteriaceae in well and from coli-enteritis suffering infants].

Ferulic Acid in the Treatment of Papulopustular Rosacea: A Randomized Controlled Study

Effect of age on the acute lethal response of the beagle to cobalt-60 gamma radiation.

Diversity within a birdsong.

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape

Effect of Topical Microencapsulated Benzoyl Peroxide on the Skin Microbiome in Rosacea: A Randomized, Double-Blind, Crossover, Vehicle-Controlled Clinical Trial

Fabrication and efficacy assessment of combination of brimonidine and ivermectin for treatment of papulopustular rosacea

Efficacy of Treatments in Reducing Facial Erythema in Rosacea: A Systematic Review

Rosacea symptoms significantly decrease after skin barrier improvement

Conjugated polymer shells on colloidal templates by seeded Suzuki–Miyaura dispersion polymerization.

Developmental expression and gene/enzyme identifications in the alpha esterase gene cluster of Drosophila melanogaster

Oral tranexamic acid treats papulopustular rosacea by improving the skin barrier

Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial

Direct determination of steroidal sulfates.

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial

CITRATE FORMATION IN MYCOBACTERIUM PHLEI

Effect of recombinant bovine basic fibroblast growth factor gel on repair of rosacea skin lesions: A randomized, single-blind and vehicle-controlled study

Poly‐d,l‐Lactic Acid Via Transdermal Microjet Drug Delivery for Treating Rosacea in Asian Patients